Predicting the outcome of platinum-based chemotherapies in epithelial ovarian cancer using the 8092C/A polymorphism of ERCC1: a meta-analysis

• Published in: Biomarkers Vol. 19; no. 2; pp. 128 - 134
• Main Authors: Yan, Li, Pei, Hu, Yu, Cao, Gui-ying, Wang, Na, Wang, Rong-miao, Zhou
• Format: Journal Article
• Language: English
• Published: England Informa UK Ltd 01.03.2014; Taylor & Francis
• Subjects: Antineoplastic Agents - pharmacology; Antineoplastic Agents - therapeutic use; Carcinoma, Ovarian Epithelial; Clinical outcome; Disease-Free Survival; DNA-Binding Proteins - genetics; Drug Resistance, Neoplasm - genetics; Endonucleases - genetics; epithelial ovarian cancer; ERCC1; Female; Genetic Association Studies; Humans; meta-analysis; Neoplasms, Glandular and Epithelial - drug therapy; Neoplasms, Glandular and Epithelial - genetics; Neoplasms, Glandular and Epithelial - mortality; Ovarian Neoplasms - drug therapy; Ovarian Neoplasms - genetics; Ovarian Neoplasms - mortality; platinum chemotherapy; Platinum Compounds - pharmacology; Platinum Compounds - therapeutic use; polymorphism; Polymorphism, Single Nucleotide; Treatment Outcome
• ISSN: 1354-750X; 1366-5804
• DOI: 10.3109/1354750X.2014.882414

Abstract Background: In the present study, we performed this meta-analysis to estimate the association between excision repair cross-complementation group 1 (ERCC1) gene polymorphism and clinical resistance to platinum-based chemotherapy in the patients with epithelial ovarian cancer (EOC). Methods: A total of 10 studies consist of 1479 EOC patients relating ERCC1 rs11615C/T and rs3212986C/A polymorphisms to the response of platinum-based chemotherapy were included in this meta-analysis. Results: The analysis showed that the AA genotype of the rs3212986C/A polymorphism in ERCC1 was associated with progression-free survival of EOC patients (HR = 1.39, 95% CI = 1.12-1.73) and that the CA or AA genotypes could influence overall survival (HR = 1.28, 95% CI = 1.05-1.56; and HR = 1.55, 95% CI = 1.17∼2.05, respectively). Conclusions: The ERCC1 rs3212986C/A polymorphism may be a useful prognostic marker in platinum-based treatment of EOC.